Clinical Trials
Roche presents positive preclinical data on Genmab antibody
Published in Pharma Investments, Ventures and Law Weekly, December 10th, 2006
The fully human IgG1,k antibody, called R1507, which is in Phase I clinical development, was selected from a large panel of antibodies and was found to be very good at binding to its target, the Insulin-like Growth factor-1 Receptor (IGF-1R). R1507 was shown to block binding of IGF-1 and IGF-2, and to potently inhibit IGF-1R signaling. In addition, R1507 was found to effectively stop tumor cell growth in different animal models.
The IGF-1R molecule has been shown to be important in tumor growth and protecting tumor cells from being killed....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Business & Finance
Angiotech Pharmaceuticals reports income of $0.19 per share - Business & Finance
Connetics reports third quarter financial results - Business & Finance
Cross Country Healthcare reports $162.9 million for third quarter 2006 - Business & Finance
Cutera reports 32% third-quarter revenue increase over same period last year - Business Update
China Medical Technologies and Chinese Academy of Sciences Institute of Acoustics form lab - Business Update
Drager Medical and Masimo announce expanded relationship - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
